A Novel Human T Cell Antigen Preferentially Expressed on Mature T Cells and Shared by Both Well and Poorly Differentiated B Cell Leukemias and Lymphomas
Overview
Authors
Affiliations
A new lymphocyte differentiation antigen shared by all normal T cells and some malignant B cells was defined by a monoclonal antibody designated 12.1. This antibody reacted with all peripheral blood T cells but not with normal B cells and B cell lines. Analysis with a fluorescence activated cell sorter showed that the expression of 12.1 antigen changes during T cell maturation. Most thymocytes, blasts of acute T cell leukemia, and cells from established leukemic T cell lines bear a small amount of 12.1 antigen. In contrast the majority of peripheral blood T cells, activated T cells, and leukemic T cells of the Sezary syndrome bear a large amount of 12.1 antigen. Unexpectedly, antibody 12.1 reacted with leukemic cells from most patients with B-type chronic lymphocytic leukemia (CLL) and some patients with lymphosarcoma cell leukemia (LSCL). Among these leukemias, expression of the 12.1 antigen was not correlated with the stage of B cell maturation, with the amount of surface immunoglobulin on the cells, or with the presence or absence of monoclonal gammapathy. In a comparative serologic analysis the antigen defined by antibody 12.1 was distinct from the p67 T cell antigen (defined by monoclonal antibody 10.2) that is also known to be expressed by B-type CLL cells.
Gurrea-Rubio M, Fox D, Castresana J Cells. 2025; 14(4).
PMID: 39996744 PMC: 11853562. DOI: 10.3390/cells14040272.
CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies.
Aragon-Serrano L, Carrillo-Serradell L, Planells-Romeo V, Isamat M, Velasco-de Andres M, Lozano F Int J Mol Sci. 2023; 24(24).
PMID: 38139340 PMC: 10743954. DOI: 10.3390/ijms242417510.
A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders.
Zhang L, Luo L, Chen J, Singh R, Baldwin 3rd W, Fox D JCI Insight. 2023; 8(23).
PMID: 37917882 PMC: 10795824. DOI: 10.1172/jci.insight.172914.
CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma.
Parameswaran N, Luo L, Zhang L, Chen J, DiFilippo F, Androjna C Leukemia. 2023; 37(10):2050-2057.
PMID: 37573404 DOI: 10.1038/s41375-023-01997-8.
CD6-mediated inhibition of T cell activation via modulation of Ras.
Henriques S, Oliveira L, Santos R, Carmo A Cell Commun Signal. 2022; 20(1):184.
PMID: 36414966 PMC: 9682754. DOI: 10.1186/s12964-022-00998-x.